BR112023004123A2 - Vacina de haste da ha para alvos positivos de anticorpos de ha - Google Patents

Vacina de haste da ha para alvos positivos de anticorpos de ha

Info

Publication number
BR112023004123A2
BR112023004123A2 BR112023004123A BR112023004123A BR112023004123A2 BR 112023004123 A2 BR112023004123 A2 BR 112023004123A2 BR 112023004123 A BR112023004123 A BR 112023004123A BR 112023004123 A BR112023004123 A BR 112023004123A BR 112023004123 A2 BR112023004123 A2 BR 112023004123A2
Authority
BR
Brazil
Prior art keywords
vaccine
influenza virus
vector
stem
disease
Prior art date
Application number
BR112023004123A
Other languages
English (en)
Inventor
Alexander Langereis Martijn
Verstegen Iwan
Alexander Maria De Haan Cornelis
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112023004123A2 publication Critical patent/BR112023004123A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

VACINA DE HASTE DA HA PARA ALVOS POSITIVOS DE ANTICORPOS DE HA. A presente invenção está relacionada a vacinas contra a infecção ou doença pelo vírus influenza para alvos com anticorpos pré-existentes contra o domínio da cabeça da HA do vírus influenza. A invenção considera um vetor recombinante expressando um polipeptídeo da haste da HA, uma vacina compreendendo o vetor ou uma célula hospedeira com o referido vetor, usos do vetor, da célula hospedeira ou da vacina e métodos para reduzir a infecção ou doença pelo vírus influenza. O vetor recombinante pode ser um ácido nucleico tal como um plasmídeo de expressão eucariótica ou um RNA, um vírus ou uma partícula de replicon (RP). Essa vacinação permite a indução de uma resposta imunológica precoce e eficaz contra a infecção ou doença induzida pelo vírus Influenza, não impedida por anticorpos de domínio de cabeça anti-HA pré-existentes.
BR112023004123A 2020-09-07 2021-09-06 Vacina de haste da ha para alvos positivos de anticorpos de ha BR112023004123A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20194937 2020-09-07
PCT/EP2021/074446 WO2022049276A1 (en) 2020-09-07 2021-09-06 Ha stem vaccine for ha antibody-positive targets

Publications (1)

Publication Number Publication Date
BR112023004123A2 true BR112023004123A2 (pt) 2023-04-04

Family

ID=72428193

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023004123A BR112023004123A2 (pt) 2020-09-07 2021-09-06 Vacina de haste da ha para alvos positivos de anticorpos de ha

Country Status (9)

Country Link
US (1) US20240024456A1 (pt)
EP (1) EP4210740A1 (pt)
JP (1) JP2023539771A (pt)
KR (1) KR20230065321A (pt)
CN (1) CN116528893A (pt)
BR (1) BR112023004123A2 (pt)
CA (1) CA3190070A1 (pt)
MX (1) MX2023002674A (pt)
WO (1) WO2022049276A1 (pt)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961982A (en) 1985-09-06 1999-10-05 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
FR2749022B1 (fr) 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
ES2321212T3 (es) 2004-05-18 2009-06-03 Alphavax, Inc. Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
KR20080103602A (ko) 2006-03-15 2008-11-27 인터벳 인터내셔널 비.브이. 재조합 모노네가바이랄러스 바이러스 벡터
US7850977B2 (en) 2007-06-21 2010-12-14 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
KR20130075732A (ko) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
MX344069B (es) 2010-10-18 2016-12-02 Intervet Int Bv Vacuna vectorizada por el herpesvirus de los pavos contra la influenza aviar en aves de corral.
ES2582324T3 (es) 2011-05-27 2016-09-12 20Med Therapeutics B.V. Nanogeles
EA033386B1 (ru) 2011-11-28 2019-10-31 Janssen Vaccines & Prevention Bv Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение
WO2016005482A1 (en) * 2014-07-10 2016-01-14 Crucell Holland B.V. Influenza virus vaccines and uses thereof
BR112017011582A2 (pt) 2014-12-04 2018-02-27 Intervet Int Bv fibroblasto de embrião de galinha imortalizado, cultura de célula, métodos para preparação de um cef importalizado, para a replicação de um vetor viral aviário e para a preparação de uma vacina, e, vacina.
AR103245A1 (es) 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
US20200323975A1 (en) 2017-12-04 2020-10-15 Intervet Inc. Vaccination with replicon particles and oil adjuvant
BR112020012162A2 (pt) 2017-12-20 2020-11-24 Intervet International B.V. diluente aprimorado para vacina contra alfa-herpesvírus associado à célula

Also Published As

Publication number Publication date
JP2023539771A (ja) 2023-09-19
US20240024456A1 (en) 2024-01-25
CN116528893A (zh) 2023-08-01
EP4210740A1 (en) 2023-07-19
CA3190070A1 (en) 2022-03-10
MX2023002674A (es) 2023-04-03
KR20230065321A (ko) 2023-05-11
WO2022049276A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
CO2021004188A2 (es) Vacuna contra el virus de la peste porcina africana
ES2555995T3 (es) Procedimiento de fabricación de vacunas virales en líneas de células madre derivadas de embriones aviares en suspensión
MX344069B (es) Vacuna vectorizada por el herpesvirus de los pavos contra la influenza aviar en aves de corral.
Schotsaert et al. Influenza vaccines: T-cell responses deserve more attention
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
US9017694B2 (en) Swine influenza hemagglutinin variants
BR112017013595A2 (pt) cassete de expressão de dna recombinante, molécula de dna recombinante, vírus herpes de peru recombinante, célula hospedeira, métodos para construção de um vírus herpes de peru recombinante, para preparação de uma vacina, para prevenir ou reduzir infecção por vírus da doença bursal infecciosa e/ou vírus da doença de newcastle ou sinais associados de doença e para vacinação das aves, vacina para aves, e, usos de um cassete de expressão e de uma vacina.
Rimmelzwaan et al. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara
Trucchi et al. Universal influenza virus vaccines: what needs to happen next?
Isakova-Sivak et al. Influenza vaccine: Progress in a vaccine that elicits a broad immune response
Wei et al. Development and characterization of a recombinant infectious bronchitis virus expressing the ectodomain region of S1 gene of H120 strain
BR112015025898A2 (pt) polipeptídeo, célula, ácido nucleico, vetor, vírus da varíola suína recombinante, composição, vacina, e uso de um peptídeo sinal
Kotomina et al. Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site
EA201791957A1 (ru) Маркерная система, в частности, для экспрессируемых бакуловирусом субъединичных антигенов
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
Kaplan et al. Vaccination of pigs with a codon-pair bias de-optimized live attenuated influenza vaccine protects from homologous challenge
Jazi et al. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
BR112023004123A2 (pt) Vacina de haste da ha para alvos positivos de anticorpos de ha
BR112018075585A2 (pt) spv recombinante multivalente
Schmidt et al. Squalene-containing licensed adjuvants enhance strain-specific antibody responses against the influenza hemagglutinin and induce subtype-specific antibodies against the neuraminidase
Lu et al. Immunopotentiators improve the efficacy of oil-emulsion-inactivated avian influenza vaccine in chickens, ducks and geese
BR112020010202A8 (pt) Cepa para vacina de influenza aviária h9 que diferencia animais infectados de vacinados, e método de preparação para a mesma
Qin et al. Biological characteristics and immunological properties in Muscovy ducks of H5N6 virus-like particles composed of HA-TM/HA-TMH3 and M1